GlassScriptPhysician profile
Young W Kang
NPI 1811946866
$24,040.40
in general payments reported to CMS, 2019-2025
72 companies · $3,783 in 2025
The $3,783 reported for 2025 was more than what 97% of Adolescent Medicine (Internal Medicine) providers received nationally (typical 2025 total: $165).
See the full distribution for Adolescent Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,517 · 2020: $2,733 · 2021: $3,666 · 2022: $4,233 · 2023: $3,301 · 2024: $3,808 · 2025: $3,783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,384.25 |
| Education | $507.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,723.80 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,081.49 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,497.27 | 2019-2025 | Evenity, Repatha, Otezla |
| Novo Nordisk INC | $1,266.92 | 2019-2025 | Ozempic, Rybelsus |
| Sumitomo Pharma America, INC. | $1,112.08 | 2023-2025 | Gemtesa |
| Amarin Pharma, INC. | $1,100.47 | 2019-2023 | |
| Pfizer INC. | $1,079.81 | 2019-2025 | |
| Astellas Pharma US INC | $976.15 | 2019-2025 | Veozah |
| Lilly USA, LLC | $871.84 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Sanofi-Aventis U.S. LLC | $794.25 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $654.67 | 2019-2025 | Jardiance, Synjardy |
| Gilead Sciences, INC. | $614.00 | 2020-2025 | |
| Scilex Pharmaceuticals INC. | $607.36 | 2019-2025 | Ztlido |
| Glaxosmithkline, LLC. | $532.92 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $495.03 | 2019-2022 |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Young Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.